First results from IEO 676 clinical study of PRRT in neuroendocrine tumors – Is there still a space for Y-90-DOTATOC?

#3705

Introduction: IEO 676 is a prospective phase II study of Peptide Receptor Radionuclide Therapy (PRRT) with Y-90-DOTATOC in progressive G1, G2, G3, neuroendocrine patients. PRRT has been in use since the late 1990s, with the introduction of 90Y-DOTATOC, which allowed objective responses in 10-30% of treated patients.

Aim(s): The aim of this phase II study is to evaluate the antitumor activity of 90Y-DOTATOC in pts affected by sst2 positive NETs, stratified for positive or negative FDG PET/CT. Although the comparison between the two patient populations is not an objective of the study, an analysis of these two groups can be carried out at a later stage, in order to evaluate the therapeutic efficacy based on the different activity administered for stratification obtained following positive-negative disease on 18F-FDG PET/CT.

Materials and methods: The protocol includes two level of administered activity: 5 cycles of 50 mCi of Y-90-DOTATOC in FDG-PET positive pts and 4 cycles in FDG negative pts.

Conference:

Presenting Author: Grana C

Authors: Grana C, Papi S, Clerici I, Rocca P, Spada F,

Keywords: PRRT, Y-90-DOTATOC, NET,